Scapho 150 Mg 150 mg Powder for solution for injection
PDF Leaflet Revision Date: 23 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Moderate to severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, and hidradenitis suppurativa.
Dosage (summary)
Adults: 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then monthly. Pediatric: Dosing based on weight.
Onset of Action / Duration
Onset: 16 weeks, Duration: Varies by indication.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Live vaccines
- Immunosuppressants
Contraindications
- Hypersensitivity
- Active infections
- Pregnancy
- Breastfeeding
Common side effects
- Upper respiratory tract infections
- Headache
- Diarrhea
- Fatigue
Counselling Points
- Monitor for signs of infection
- Avoid live vaccines
- Use contraception during treatment
Serious warnings
- Risk of serious infections
- Hypersensitivity reactions
- Inflammatory bowel disease
Important Disclaimer
The Scapho 150 Mg 150 mg Powder for solution for injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
